Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Golam (Cambridge, United Kingdom), M. Sadatsafavi (Vancouver, Canada), M. Alacqua (Cambridge, United Kingdom), R. Beasley (Wellington, New Zealand), J. Fitzgerald (Vancouver, Canada), T. Harrison (Nottingham, United Kingdom), R. Hughes (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), J. Olaguibel (Pamplona, Spain), E. Rapsomaniki (Cambridge, United Kingdom), H. Reddel (Sydney, Australia), C. Janson (Uppsala, Sweden). Exacerbation burden in mild asthma: Evidence from the NOVELTY study. 969

Member's Comments

No comment yet.

Related content which might interest you: Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort Source: Eur Respir J, 58 (3) 2003927; 10.1183/13993003.03927-2020 Year: 2021 Characteristics by physician-assigned severity of asthma, asthma+COPD and COPD patients in the NOVELTY study Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 Montelukast reduces viral-induced asthma exacerbations: the PREVIA study Source: Eur Respir J 2004; 24: Suppl. 48, 212s Year: 2004 Factors associated with exacerbations in patients with COPD: NOVELTY study Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Evolution from mild to severe asthma; the severe asthma clinic perspective Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 The burden of exacerbations in mild asthma: a systematic review Source: ERJ Open Res, 6 (3) 00359-2019; 10.1183/23120541.00359-2019 Year: 2020 Characterising asthma exacerbations in the CAPTAIN trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Factors associated with physician assessment of severity of asthma or COPD in NOVELTY Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases Year: 2020 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Severe asthma: one disease many definitions Source: International Congress 2019 – Asthma and the world Year: 2019 Biomarkers for the management of severe asthma: a survey Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases Year: 2021 Assessing the risk of future severe asthma exacerbations using CARAT questionnaire and lung function Source: Annual Congress 2013 –Lung function tests to monitor airway diseases Year: 2013 Acute severe asthma: evidence-based management of asthma exacerbations Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond Year: 2008 Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Preliminary outcomes of the CREWS study Source: International Congress 2015 – Best abstracts in chronic care Year: 2015 Severe asthma: classification and treatment Source: Virtual Congress 2021 – Clinical year in review Year: 2021 Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations Source: International Congress 2015 – Management of asthma and COPD in primary care Year: 2015